Cancer News
OncoLink Cancer News - HealthDay


Recurrent Cutaneous Melanoma Hazard Rates Vary With Stage

Thursday, December 22, 2011 (Last Updated: 12/27/2011)

THURSDAY, Dec. 22 (HealthDay News) -- The hazard rates (HRs) for recurrent and secondary cutaneous melanoma (CM) after incident stage IA melanoma are low, while the HRs of recurrence after incident stage IB, II, and III CM are high, according to a study published in the January issue of the Journal of the American Academy of Dermatology.

Ulrike Leiter, M.D., from the Eberhard Karls University in Tübingen, Germany, and colleagues investigated the stage- and time-dependent HRs for recurrent and secondary CM. From 1976 through 2007, the German Central Malignant Melanoma Registry recorded follow-up data for 33,384 patients with incident CM in stages I to III. HRs and Kaplan-Meier estimates of survival were calculated. A total of 4,999 patients had recurrences (7.1, 32.8, 51.0 percent in stage I, II, and III, respectively).

The investigators found that the 10-year recurrence-free survival was 78.9 percent overall (89.0, 56.9, and 36.0 percent in stage I, II, and III CM, respectively). The HR for recurrent CM was consistently low for stage IA (≤1 recurrence per 125 persons per year). The HRs were higher for stage IB for the first three years, and in general for stages II to III (≥1 recurrence per 40 persons per year). A total of 2.3 percent of patients developed secondary melanomas, with the HR low at less than one recurrence per 220 persons per year.

"We propose that patients at high risk with [a] HR of more than one recurrence per 40 persons per year should be considered in an intensified follow-up schedule," the authors write.

Abstract
Full Text (subscription or payment may be required)

Specialties Hematology & Oncology
Neurology
Urology
Internal Medicine
Family Practice

Copyright © 2011 HealthDay. All rights reserved.


I Wish You Knew

The role of cancer biology and genetics in cancer

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More